Athenex presents interim data from anchor study of kur-502 (allogeneic cd19 car-nkt cells) in relapsed or refractory lymphoma and leukemia at 63rd ash annual meeting and exposition

Results from five patients showed best responses of 2 partial responses (pr), 1 complete response with incomplete hematological recovery (cri) and 1 complete response (cr).
ATNX Ratings Summary
ATNX Quant Ranking